Apple once again outperformed Masimo in the race for accurate blood oxygen level measurement

Apple Wins Temporary Victory in Dispute with Masimo

For several years Apple and medical equipment manufacturer Masimo have fought for control over the pulse‑oximeter technology built into smartwatches. In the end, the U.S. International Trade Commission (ITC) declined to consider Masimo’s second patent infringement complaint.

How the Case Unfolded
Stage Date What Happened
First Ban Masimo secured a restriction on importing Apple Watch in the United States after discovering an infringement of its oxygen‑sensor patent. Apple’s Adjustment The company did not disable the feature entirely but shifted most of its functionality to the iPhone. The ITC deemed this sufficient and allowed the watches to be sold. Reopening of the Case March 18, 2026 An administrative ITC judge ruled that the updated implementation does not infringe Masimo’s patent. Motion for Review March 25 Apple and Masimo filed requests with the ITC. Responses to Each Other March 30 Both sides presented arguments in response to the motions. Final Decision April 17 The Commission declined to review the initial ruling and closed the proceeding.

What This Means for Apple
Apple noted that thanks to the ITC decision it can continue offering blood‑oxygen measurement to its users. The company emphasized that over the past six years almost all of Masimo’s claims have been dismissed and that they will defend their innovations while focusing on building better products.

What Comes Next for Masimo
Masimo retains the right to appeal, but at present its path to overturning the ITC decision remains open.